Research has shown there are plenty of perks of using a medication like Ozempic for weight loss. But, given that this is a drug, there are some potential downsides to consider, too. New research published in JAMA Network Open links GLP-1 receptor agonists—a class of medications that includes semaglutide medications like Ozempic and Wegovy—to a loss of bone density.

Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and Saxenda. Here's what to know.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

In July, the U.S. Food and Drug Administration warned that people are overdosing on compounded semaglutide injectable products.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

"Weight loss medications are not one size fits all and patients should always discuss options with a trusted medical professional," one expert told Newsweek.